Literature DB >> 21761403

Single brain metastasis: whole-brain irradiation plus either radiosurgery or neurosurgical resection.

Dirk Rades1, Theo Veninga, Dagmar Hornung, Oliver Wittkugel, Steven E Schild, Jan Gliemroth.   

Abstract

BACKGROUND: The current study was conducted to compare neurosurgical resection (NR) followed by whole-brain irradiation (WBI) (NR + WBI) with WBI followed by radiosurgery (WBI + RS) in patients with a single brain metastasis.
METHODS: The outcome of 41 patients treated with WBI + RS was retrospectively compared with 111 patients who received NR ;+ WBI with respect to local control of the treated metastasis and survival. Eleven additional potential prognostic factors were investigated, including WBI schedule, patient age, patient gender, Karnofsky performance score (KPS), primary tumor type, extracerebral metastases, recursive partitioning analysis (RPA) class, interval between the first diagnosis of cancer to the treatment of brain metastasis, metastatic site, maximum diameter of the metastasis, and graded prognostic assessment (GPA) score.
RESULTS: The 1-year local control rates were 87% after WBI + RS and 56% after NR + WBI (P = .001). Using the Cox proportional hazards model, the treatment regimen remained significant (risk ratio [RR], 2.46; 95% confidence interval [95% CI], 1.29-5.17 [P = .005]). On the multivariate analysis, local control was also found to be associated with the maximum diameter of the metastasis. The 1-year survival rates were 61% after WBI + RS and 53% after NR + WBI (P = .16). Acute and late toxicities were similar in both groups. On the multivariate analysis, KPS, extracerebral metastases, RPA class, and the GPA score were found to be independent predictors of survival.
CONCLUSIONS: The use of WBI + RS resulted in significantly better local control of the treated metastasis than NR + WBI. Survival was not found to be significantly different in either group. Because WBI + RS is less invasive than NR + WBI, it appears to be preferable for many patients with a single brain metastasis. These results should be confirmed in a randomized trial.
Copyright © 2011 American Cancer Society.

Entities:  

Mesh:

Year:  2011        PMID: 21761403     DOI: 10.1002/cncr.26379

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  9 in total

1.  Number of cerebral lesions predicts freedom from new brain metastases after radiosurgery alone in lung cancer patients.

Authors:  Dirk Rades; Stefan Huttenlocher; Mai Trong Khoa; Pham VAN Thai; Dagmar Hornung; Steven E Schild
Journal:  Oncol Lett       Date:  2015-06-11       Impact factor: 2.967

2.  A Novel Score Combining Magnetic Resonance Spectroscopy Parameters and Systemic Immune-Inflammation Index Improves Prognosis Prediction in Non-Small Cell Lung Cancer Patients With Brain Metastases After Stereotactic Radiotherapy.

Authors:  Dong Guo; Jiafeng Liu; Yanping Li; Qingqing Chen; Yunzheng Zhao; Xinwei Guo; Shuchai Zhu; Shengjun Ji
Journal:  Front Oncol       Date:  2022-06-08       Impact factor: 5.738

3.  Intraoperative neuromonitoring for function-guided resection differs for supratentorial motor eloquent gliomas and metastases.

Authors:  Thomas Obermueller; Michael Schaeffner; Ehab Shiban; Doris Droese; Chiara Negwer; Bernhard Meyer; Florian Ringel; Sandro M Krieg
Journal:  BMC Neurol       Date:  2015-10-20       Impact factor: 2.474

4.  The Value of the Systemic Immune-Inflammation Index in Predicting Survival Outcomes in Patients with Brain Metastases of Non-Small-Cell Lung Cancer Treated with Stereotactic Radiotherapy.

Authors:  Yanan Zhang; Zeyang Chen; Feng Jin; Dong Guo; Qingqing Chen; Zhengcao Liu; Shengjun Ji; Guanqi Gao
Journal:  Mediators Inflamm       Date:  2021-10-29       Impact factor: 4.711

Review 5.  Management of brain metastasis. Surgical resection versus stereotactic radiotherapy: a meta-analysis.

Authors:  David T Krist; Anant Naik; Charee M Thompson; Susanna S Kwok; Mika Janbahan; William C Olivero; Wael Hassaneen
Journal:  Neurooncol Adv       Date:  2022-03-09

6.  Risks of postoperative paresis in motor eloquently and non-eloquently located brain metastases.

Authors:  Thomas Obermueller; Michael Schaeffner; Julia Gerhardt; Bernhard Meyer; Florian Ringel; Sandro M Krieg
Journal:  BMC Cancer       Date:  2014-01-14       Impact factor: 4.430

7.  A new prognostic instrument to predict the probability of developing new cerebral metastases after radiosurgery alone.

Authors:  Stefan Huttenlocher; Liesa Dziggel; Dagmar Hornung; Oliver Blanck; Steven E Schild; Dirk Rades
Journal:  Radiat Oncol       Date:  2014-09-20       Impact factor: 3.481

Review 8.  The Management of Brain Metastases-Systematic Review of Neurosurgical Aspects.

Authors:  Martin A Proescholdt; Petra Schödel; Christian Doenitz; Tobias Pukrop; Julius Höhne; Nils Ole Schmidt; Karl-Michael Schebesch
Journal:  Cancers (Basel)       Date:  2021-03-31       Impact factor: 6.639

9.  The Debatable Benefit of Gross-Total Resection of Brain Metastases in a Comprehensive Treatment Setting.

Authors:  Stephanie T Jünger; Lenhard Pennig; Petra Schödel; Roland Goldbrunner; Lea Friker; Martin Kocher; Martin Proescholdt; Stefan Grau
Journal:  Cancers (Basel)       Date:  2021-03-21       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.